Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23765893 | 1.00 | CRBN (0.47) | CRBNRIPK2MAP1LC3BBRD4STAT3 | |
| SCHEMBL23765755 | 0.97 | CRBN (0.47) | CRBNRIPK2MAP1LC3BBRD4STAT3 | |
| SCHEMBL25756369 | 0.96 | CRBN (0.47) | CRBNRIPK2MAP1LC3BBRD4 | |
| SCHEMBL23766010 | 0.95 | MAP1LC3B (0.47) | CRBNMAP1LC3BBRD4STAT3 | |
| SCHEMBL25756217 | 0.95 | MAP1LC3B (0.47) | CRBNMAP1LC3BBRD4STAT3 | |
| SCHEMBL23766141 | 0.95 | MAP1LC3B (0.47) | CRBNMAP1LC3BBRD4STAT3 | |
| SCHEMBL24068351 | 0.94 | MAP1LC3B (0.46) | CRBNMAP1LC3BBRD4STAT3 | |
| SCHEMBL23766083 | 0.94 | MAP1LC3B (0.47) | CRBNMAP1LC3BBRD4STAT3 | |
| SCHEMBL24068867 | 0.94 | MAP1LC3B (0.47) | CRBNRIPK2MAP1LC3BBRD4STAT3 | |
| SCHEMBL25755912 | 0.94 | MAP1LC3B (0.47) | CRBNMAP1LC3BBRD4STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | CRBN 284/4885RIPK2 776/4885MAP1LC3B 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.